AUTHORS
Alexander P. Boardman, MD, Mary Clark, PhD2, John Baird, MD3, Vivian Song4, Caroline Worrell5, Elizabeth Miranda6, Lu Chen, PhD7, Michelle Mott8, Jae H Park, MD9, Craig Sauter, MD10, Gilles Salles I, MD, PhD11, Avyakta Kallam, MBBS12, Steven T Rosen, MD13, Geoffrey Shouse, DO PhD14, Alexey V. Danilov, MD, PhD15, Lili Wang, MD, PhD16, Tanya Siddiqi, MD17
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Introduction
Richter’s transformation (RT) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma typically to large B cell lymphoma (LBCL) that is difficult to treat and has a poor prognosis. Outcomes of relapsed/refractory (R/R) RT after CD19 chimeric antigen receptor T cell therapy (CAR T) are inferior to those of de novo LBCL. Combination of the BTK inhibitor (BTKi) ibrutinib and PD-1 checkpoint inhibitor nivolumab (nivo) are promising in RT especially as a bridge to allogeneic hematopoietic cell transplantation (alloHCT). Thus, use of this combination as bridging and maintenance therapy may enhance response to CAR T. Here we present initial reporting of a phase 2 investigator-initiated multicenter study combining ibrutinib, nivo, and lisocabtagene maraleucel (liso-cel) in patients (pts) with R/R RT (NCT05672173).
Methods
Pts had histologically confirmed RT with measurable disease after prior therapy for RT, adequate organ function, and were eligible to receive liso-cel and ibrutinib per package inserts. Prior BTKi was allowed. Pts with de novo RT or who received prior PD1 or PD-L1 inhibitors were excluded. Ibrutinib (420mg daily) commenced at the time of study entry and continued throughout study treatment. Nivo (240mg Q2 weeks) was administered for at least 2 doses prior to apheresis then resumed immediately following apheresis (induction) and was stopped during lymphodepletion (LD) and liso-cel infusion until Day +28 [Cycle (C)1]. Nivo was restarted at 240mg on days 1 and 15 of C2 and then 480mg nivo on day 1 of C3-12 (Maintenance). CLL measurable residual disease (MRD) on peripheral blood and bone marrow was assessed by flow cytometry and/or Clonoseq. This trial had a planned sample size of 12 pts, including a 6 pt-safety lead-in to assess the unacceptable toxicity (UT) rate during C1. The primary endpoint was complete response (CR) by Lugano criteria after C3. Secondary endpoints were CR rate, overall response rate, 2-year duration of response, progression free survival (PFS), and overall survival, and MRD after liso-cel. Planned correlatives will be reported in the future.
Results
Nine pts were enrolled across 2 centers: 1 went off study for severe graft-versus-host disease (GVHD) recurrence after nivo initiation pre apheresis, 1 died from rapid disease progression pre apheresis, and 7 pts received liso-cel. The trial subsequently closed to accrual early due to funding. The median age was 64 (range, 52-77) years. The median number of prior therapies for RT was 1 (range, 1-2). One pt had prior alloHCT and 4 pts had prior BTKi (n=3 acalabrutinib, n=1 zanubrutinib, n=1 pirtobrutinib). Five pts were refractory to first-line therapy for RT. Two pts required bridging therapy for disease control in addition to induction (n=1 polatuzumab/rituximab; n=1 cyclophosphamide/rituximab + gemcitabine/oxaliplatin).
Protocol therapy was well-tolerated with no UT. The most common grade (G)3 or higher adverse events post induction were hypertension (33%) and lymphopenia (22%); only 1 pt had G3 atrial fibrillation requiring dose reduction of ibrutinib. One pt experienced G3 GVHD of the oral mucosa and G2 GVHD of the liver, skin, and eyes after the second dose of nivo pre apheresis and came off study. After LD/liso-cel infusion, 4/7 pts developed cytokine release syndrome (CRS) with 3 G1 and 1 G2 events observed. Immune effector cell associated neurotoxicity syndrome (ICANS) occurred in 1 pt (G1). Hematological toxicities were the most common G3-4 toxicities during/after C1, 1 pt had G3 atrial flutter, and 2 pts had G3 hypertension. Median number of cycles completed after LD/liso-cel infusion was 10 (range, 1-12).
Of the 7 pts who received liso-cel, responses after C3 were: 2 CR, 3 partial response (PR), and 1 progressive disease (PD; after C2), with 1 pt pending completion of C2-3. One PR at C3 converted to CR after C6; 1 PR progressed after C6 (and died after other therapy 5 months later with acute myelogenous leukemia unrelated to treatment); 1 PR progressed at C11 and transitioned to other therapy and alloHCT. With a median follow-up of 13 months for surviving pts, the median PFS has not been reached. MRD results are being evaluated.
Conclusions
In this initial reporting of combination therapy with ibrutinib, nivo, and liso-cel, a subset of pts with R/R RT had deep and durable responses. The safety profile was acceptable with no UT and few CRS/ICANS events. Longer follow up will be reported.
DISCLOSURES
Alexander P. Boardman, MD: Incyte - Honoraria; Incyte - Research Funding; BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony)